This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the future use of Exparel in light of the recent patent coverage loss and the FDA approval of an exparel generic
Ticker(s): PCRX, VRTXWho's the expert?
Institution: Self
- Board certified Anesthesiologist
-
treats ~5-8 patient per day using post-surgical analgesia to manage pain
-
Has used Zynrelef for over 100 patients post herniorrhaphy, bunionectomy, or TKA(total knee arthroplasty) and is familiar with the recent label expansion.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
